Ferric citrate - Keryx

Drug Profile

Ferric citrate - Keryx

Alternative Names: Auryxia; Ferric citrate dihydrate; Fexeric; JTT-751; KRX-0502; Nephoxil; Riona; Tetraferric tricitrate decahydrate; Zerenex

Latest Information Update: 18 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Panacor Bioscience; Panion & BF Biotech
  • Developer Japan Tobacco; Keryx Biopharmaceuticals; Panion & BF Biotech; Torii Pharmaceutical
  • Class Antianaemics; Ferric compounds; Hyperphosphataemia therapies; Small molecules; Tricarboxylic acids
  • Mechanism of Action Iron replacements; Phosphate binding protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Hyperphosphataemia

Highest Development Phases

  • Marketed Hyperphosphataemia
  • Preregistration Iron deficiency anaemia

Most Recent Events

  • 18 Jul 2017 Japan Tobacco completes a phase I trial in Iron deficiency anaemia in Japan, before July 2017 (JapicCTI-173502)
  • 08 Mar 2017 FDA assigns PDUFA action date of 06/11/2017 for Ferric citrate for Iron deficiency anaemia (In adults)
  • 17 Feb 2017 Japan Tobacco initiates enrolment in a phase I trial for Iron deficiency anaemia in Japan (JapicCTI-173502)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top